Cord blood stem cell therapy - Aastrom Biosciences
Alternative Names: CB-I cord blood cell therapyLatest Information Update: 17 Nov 2003
At a glance
- Originator Aastrom Biosciences
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 17 Nov 2003 Discontinued - Phase-III for Haematological malignancies in USA (unspecified route)
- 28 Feb 2001 Phase-III clinical trials in Haematological malignancies in USA (unspecified route)